Skip Navigation

Neuro-Oncology 2008 10(1):2-9; doi:10.1215/15228517-2007-041
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hägerstrand, D.
Right arrow Articles by Östman, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hägerstrand, D.
Right arrow Articles by Östman, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Society for Neuro-Oncology

Gene expression analyses of grade II gliomas and identification of rPTPβ/{zeta} as a candidate oligodendroglioma marker

Daniel Hägerstrand, Anja Smits, Anna Eriksson, Sunna Sigurdardottir, Tommie Olofsson, Magdalena Hartman, Monica Nistér, Hannu Kalimo and Arne Östman

Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden (D.H., A.E., M.N., A.Ö.); Department of Neuroscience, Uppsala University, Uppsala University Hospital, Uppsala, Sweden (A.S.); Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala University Hospital, Uppsala, Sweden (S.S.); Department of Genetics and Pathology, Uppsala University, Rudbeck Laboratory, Uppsala, Sweden (T.O., M.H., H.K.); Department of Pathology, Helsinki University and University Hospital, Helsinki, Finland (H.K.)

Address correspondence to Arne Östman, Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, S-171 76 Stockholm, Sweden (arne.ostman{at}ki.se).


   Abstract

Grade II gliomas are morphologically and clinically heterogeneous tumors for which histopathological typing remains the major tool for clinical classification. To what extent the major histological subtypes—astrocytomas, oligodendrogliomas, and oligoastrocytomas—constitute true biological entities is largely unresolved. Furthermore, morphological classification is often ambiguous and would be facilitated by specific subtype markers. In this study, 23 grade II gliomas were expression-profiled and subjected to hierarchical clustering. All six oligodendrogliomas were grouped together in one of two major clusters; a significant correlation was thus observed between gene expression and histopathological subtype. Supervised analyses were performed to identify genes differentiating oligodendrogliomas from other grade II tumors. In a leave-one-out test using 10 features for classification, 20 out of 23 tumors were correctly classified. Among the most differentially expressed genes was rPTPβ/{zeta}. The expression of the rPTP β/{zeta} protein in oligodendrogliomas and astrocytomas was further validated by immunohistochemistry in an independent set of tumors. All 11 oligodendrogliomas of this set displayed strong staining. In contrast, neoplastic astrocytes were mostly negative for rPTPβ/{zeta} staining. In summary, this study demonstrates a correlation between gene expression pattern and histological subtype in grade II gliomas. Furthermore, the results from the immunohistochemical analyses of rPTPβ/{zeta} expression should prompt further evaluation of this protein as a novel oligodendroglioma marker.

Keywords: Grade II glioma, histological marker, microarray, oligodendroglioma, rPTPβ/{zeta}

Received June 29, 2006; Accepted December 31, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.